Improved duodenal ulcer healing with pantoprazole compared with ranitidine

Rensburg, C. J. Van; Eeden, P. J. Van; Marks, I. N.; Žák, J.; Simjee, A. E.; Moola, S.; Spies, S K; Buchel, Elwin; Grundling, Hendrik de Klerk; Zyl, J. H. Van; Mekel, R. C. P. M.

doi:10.1097/00042737-199408000-00018

Cited by 7 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ulcer healing rates achieved with the 1‐week (ITT = 88%, PP = 90%) and 2‐week (ITT = 77%, PP = 78%) treatment groups appears to be higher than the 61% 2‐week healing rates previously reported for a similar population 7 . While this may be explained by the higher proton pump inhibitor dosage used in the eradication regimens, Lam et al .…”

Section: Discussionmentioning

confidence: 70%

“…The ulcer healing rates achieved with the 1-week (ITT 88%, PP 90%) and 2-week (ITT 77%, PP 78%) treatment groups appears to be higher than the 61% 2-week healing rates previously reported for a similar population. 7 While this may be explained by the higher proton pump inhibitor dosage used in the eradication regimens, Lam et al have recently focused attention on the bene®cial effect of H. pylori suppression (with or without eradication) on duodenal ulcer healing. 8 We could not document any case of primary resistance to clarithromycin in the population studied.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Two‐week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing

Louw

Rensburg

Hanslo

et al. 1998

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Two‐week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing

Louw

Rensburg

Hanslo

et al. 1998

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…The proportion of patients healed after 2 weeks and 4 weeks of drug treatment was significantly higher for pantoprazole than ranitidine in all trials [36][37][38][39][40][41]. Two of these studies [36,37] found similar rates of pain relief for pantoprazole and ranitidine whereas the others demonstrated that pantoprazole was associated with faster pain relief. The rates of duodenal ulcer relapse over 12 months following healing with 40 mg pantoprazole or 300 mg ranitidine were comparable [42].…”

Section: Duodenal Ulcer 731 Pantoprazole Versus Ranitidinementioning

confidence: 99%

“…Comparison of pantoprazole and ranitidine in duodenal ulcer after 4 weeks of treatment (from[36,[38][39][40]). …”

mentioning

confidence: 99%

Pantoprazole: a new and more specific proton pump inhibitor

Garner¹,

Fadlallah

1997

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Pantoprazole is the third proton pump inhibitor (PPI) to be launched for the treatment of acid-peptic diseases. Like other drugs in this class, pantoprazole causes long-lasting inhibition of acid secretion by inactivating the parietal cell H+/K+-ATPase. Compared with H2 antagonists, pantoprazole results in faster pain relief, more rapid ulcer healing, healing of resistant ulcers and far greater efficacy in oesophageal reflux disease. The three PPIs currently available display almost identical efficacy in the treatment of acid-peptic diseases and when included as part of Helicobacter pylori eradication regimes. However, pantoprazole shows improvements in selectivity and pharmacokinetic properties compared with omeprazole and lansoprazole. The bioavailability of pantoprazole is considerably higher than omeprazole, remains constant upon repeated dosing, and is unaffected by food. Significantly, pantoprazole does not influence hepatic cytochrome P450 activity and does not therefore interact with co-administered drugs. This is in contrast to omeprazole, which inhibits P450, and lansoprazole, which appears to weakly induce multiple metabolic pathways. Although pantoprazole is entering an antisecretory market dominated by omeprazole and ranitidine, it has a number of potential advantages. In this respect it is worth recalling that enhanced specificity and the absence of drug interactions were decisive factors in determining market share in the H2 antagonist era. Pantoprazole may therefore achieve significant market penetration, particularly at the expense of lansoprazole and the H2 blockers.

show abstract

Ulcer Disease andHelicobacter Pylori

Chiba¹

2004

Evidence‐based Gastroenterology and Hepatology

View full text Add to dashboard Cite

Improved duodenal ulcer healing with pantoprazole compared with ranitidine

Cited by 7 publications

References 0 publications

Two‐week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing

Two‐week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing

Pantoprazole: a new and more specific proton pump inhibitor

Ulcer Disease andHelicobacter Pylori

Contact Info

Product

Resources

About